CLOCK and cancer: The DNA methylation levels for other clock CpGs may have subtle treatment-related changes (i.e., cannot be detected individually at the epigenome-wide significance level) and contribute cumulatively to the overall observed difference in EAA between exposed and unexposed groups for specific cancer treatment.